Want to see APNHY full AI Analyst Report?
APNHY Stock Chart & Stats
$9.32
$0.00(0.00%)
At close: 4:00 PM EDT
$9.32
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$5.24 - $10.03
Previous CloseN/A
Volume4.00
Average Volume (3M)37.00
Market Cap
$4.12B
Enterprise Value$4.78K
Total Cash (Recent Filing)$15.87B
Total Debt (Recent Filing)$15.44B
Price to Earnings (P/E)26.1
Beta0.21
Next Earnings
Mar 11, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.28%
Share Statistics
EPS (TTM)5.87
Shares Outstanding432,921,450
10 Day Avg. Volume113
30 Day Avg. Volume37
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)0.86
Price to Sales (P/S)2.00
P/FCF Ratio14.78
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.7
Revenue Forecast (FY)$2.31B
Bulls Say, Bears Say
Bulls Say
Deleveraging And Net CashMaterial deleveraging and a net cash position strengthen Aspen’s financial resilience and reduce interest and refinancing pressure. This gives management greater flexibility to fund manufacturing growth, support commercial expansion, and allocate capital without relying heavily on additional borrowing.
Improved Cash GenerationThe sharp rebound in free cash flow indicates that earnings recovery is translating into internally generated funding. Stronger cash conversion can support investment in complex products, reduce leverage, and provide durable capacity for shareholder returns or strategic opportunities.
Diversified Growth PlatformsAspen’s growth outlook is supported by multiple platforms rather than a single product: commercial medicines, sterile manufacturing, injectables, and GLP-1 expansion. This mix can improve growth durability as restructuring benefits and new market registrations broaden future revenue sources.
Bears Say
Revenue Contraction And Weaker ReturnsThe revenue decline shows that Aspen’s earnings rebound has not yet been matched by durable top-line growth. Lower margins than in earlier years and modest ROE also indicate weaker profit efficiency, which could limit the sustainability of shareholder returns if growth remains subdued.
Loss Of Manufacturing ContractThe lost mRNA contract demonstrates that manufacturing revenue can be materially affected by contract concentration and changing customer programs. Although EBITDA recovered through restructuring, replacing the associated volume remains important for sustaining scale and the division’s longer-term revenue base.
APAC Divestment Reduces Cash FlowThe divestment improves immediate balance-sheet flexibility but removes an earnings and cash-generating business from Aspen’s portfolio. Lower recurring free cash flow raises the importance of successful reinvestment in remaining operations and execution of the company’s growth pipeline.
Aspen Pharmacare News
APNHY FAQ
What was Aspen Pharmacare’s price range in the past 12 months?
Aspen Pharmacare lowest stock price was $5.24 and its highest was $10.03 in the past 12 months.
What is Aspen Pharmacare’s market cap?
Aspen Pharmacare’s market cap is $4.12B.
When is Aspen Pharmacare’s upcoming earnings report date?
Aspen Pharmacare’s upcoming earnings report date is Mar 11, 2027 which is in 172 days.
How were Aspen Pharmacare’s earnings last quarter?
Aspen Pharmacare released its earnings results on Sep 02, 2026. The company reported $0.161 earnings per share for the quarter.
Is Aspen Pharmacare overvalued?
According to Wall Street analysts Aspen Pharmacare’s price is currently Overvalued.
Does Aspen Pharmacare pay dividends?
Aspen Pharmacare pays a Annually dividend of $0.144 which represents an annual dividend yield of 1.28%. See more information on Aspen Pharmacare dividends here
What is Aspen Pharmacare’s EPS estimate?
Aspen Pharmacare’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aspen Pharmacare have?
Aspen Pharmacare has 432,921,450 shares outstanding.
What happened to Aspen Pharmacare’s price movement after its last earnings report?
Aspen Pharmacare reported an EPS of $0.161 in its last earnings report. Following the earnings report the stock price went down -7.008%.
Which hedge fund is a major shareholder of Aspen Pharmacare?
Currently, no hedge funds are holding shares in APNHY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aspen Pharmacare Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.86%
12-Months-Change
Fundamentals
Return on Equity
1.28%
Trailing 12-Months
Asset Growth
-13.61%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Aspen Pharmacare
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and markets specialty and branded pharmaceutical products in Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers injectables for therapeutic areas, such as anaesthetics, anticoagulants, antithrombotic agents, analgesics, and hormone replacement medicines under the Arixtra, Diprivan, Fraxiparine, Marcaine, Sustanon, and Xylocaine brands; over-the-counter medicines under the Emla, Maltofer, Ovestin, Solpadeine, and Xylocaine brands; and prescription products for anti-inflammatories, immunosuppressants, hypothyroidism, anti-gout, analgesics, and corticosteroids under the Eltroxin, Imuran, Lipitor, Lyrica, and Zyloric brands. It also manufactures active pharmaceutical ingredients, finished dose forms, and heparins, as well as steriles, oral solid doses, liquids, semi-solids, and biologicals. The company exports its products. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.
APNHY Company Deck
APNHY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive. Management highlighted 14% group normalized EBITDA growth, 28% NHEPS growth, ZAR 3.8 billion of free cash flow, a net cash position, successful recovery of the sterile manufacturing business and guidance for at least ZAR 9 billion of EBITDA and more than 50% NHEPS growth in financial year 2027. These positives outweighed the flat group revenue, manufacturing revenue decline, restructuring and impairment charges, geopolitical effects and near-term Canadian GLP-1 API uncertainty.View all APNHY earnings summariesTechnical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Perrigo Company
―
Teva Pharmaceutical
―
Amneal Pharmaceuticals
―